6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
prescribing	NN	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
.	.	.	.	.	N	O

Hepatotoxicity	NNP	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
Colitis	NNP	colitis	colitis	coliti	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
Perforation	NNP	perforation	perforation	perfor	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Severe	NNP	severe	severe	sever	N	B-Severity
Cutaneous	NNP	cutaneous	cutaneous	cutan	N	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O

most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Gilead	NNP	gilead	gilead	gilead	N	O
Sciences	NNPS	sciences	science	scienc	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
GILEAD	NNP	gilead	gilead	gilead	N	O
-	:	-	-	-	N	O
5	CD	5	5	5	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Chronic	NNP	chronic	chronic	chronic	N	O
Lymphocytic	NNP	lymphocytic	lymphocytic	lymphocyt	N	O
Leukemia	NNP	leukemia	leukemia	leukemia	Y	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
subject	JJ	subject	subject	subject	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
from	IN	from	from	from	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
which	WDT	which	which	which	N	O
218	CD	218	218	218	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
relapsed	JJ	relapsed	relapsed	relaps	N	O
CLL	NNP	cll	cll	cll	Y	O
received	VBD	received	received	receiv	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
8	CD	8	8	8	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
was	VBD	was	wa	wa	N	O
5	CD	5	5	5	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
54	CD	54	54	54	N	O
(	(	(	(	(	N	O
49%	CD	49%	49%	49%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBD	reported	reported	report	N	O
for	IN	for	for	for	N	O
subjects	NNS	subjects	subject	subject	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
were	VBD	were	were	were	N	O
pneumonia	VBN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
.	.	.	.	.	N	O

Thirty	NNP	thirty	thirty	thirti	N	O
-	:	-	-	-	N	O
nine	CD	nine	nine	nine	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
35%	CD	35%	35%	35%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
dose	JJ	dose	dose	dose	N	O
interruptions	NNS	interruptions	interruption	interrupt	N	O
and	CC	and	and	and	N	O
sixteen	JJ	sixteen	sixteen	sixteen	N	O
subjects	NNS	subjects	subject	subject	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
dose	JJ	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
or	CC	or	or	or	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reasons	NNS	reasons	reason	reason	N	O
for	IN	for	for	for	N	O
dose	JJ	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
were	VBD	were	were	were	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
and	CC	and	and	and	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
summarize	JJ	summarize	summarize	summar	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
and	CC	and	and	and	N	O
placebo	NN	placebo	placebo	placebo	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
CLL	NNP	cll	cll	cll	Y	O
Patients	NNPS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
Occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
2%	CD	2%	2%	2%	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Subjects	NNP	subjects	subject	subject	N	O
Receiving	NNP	receiving	receiving	receiv	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O

Zydelig	NNP	zydelig	zydelig	zydelig	N	O
RN	NNP	rn	rn	rn	N	O
110	CD	110	110	110	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
RN	NNP	rn	rn	rn	N	O
108	CD	108	108	108	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O

R	NN	r	r	r	N	O

:	:	:	:	:	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O

nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

gastroesophageal	NN	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	NN	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

headache	NN	headache	headache	headach	Y	B-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
35	CD	35	35	35	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

chills	NNS	chills	chill	chill	Y	B-AdverseReaction
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

pain	NN	pain	pain	pain	Y	B-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

rash	NN	rash	rash	rash	Y	B-AdverseReaction
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O

nasal	JJ	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

arthralgia	RB	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
Reported	NNP	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
CLL	NNP	cll	cll	cll	Y	O
Patients	NNPS	patients	patient	patient	N	O
Occurring	VBG	occurring	occurring	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
5%	CD	5%	5%	5%	N	O
Higher	JJR	higher	higher	higher	N	O
Incidence	NN	incidence	incidence	incid	N	O
in	IN	in	in	in	N	O
Subjects	NNP	subjects	subject	subject	N	O
Receiving	NNP	receiving	receiving	receiv	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O

Zydelig	NNP	zydelig	zydelig	zydelig	N	O
RN	NNP	rn	rn	rn	N	O
110	CD	110	110	110	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
RN	NNP	rn	rn	rn	N	O
108	CD	108	108	108	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Parameter	NNP	parameter	parameter	paramet	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O

Grades	NNS	grades	grade	grade	N	O

were	VBD	were	were	were	N	O
obtained	VBN	obtained	obtained	obtain	N	O
per	IN	per	per	per	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
version	NN	version	version	version	N	O
4.03	CD	4.03	4.03	4.03	N	O
.	.	.	.	.	N	O
R	NN	r	r	r	N	O
:	:	:	:	:	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
66	CD	66	66	66	N	O
(	(	(	(	(	N	O
60	CD	60	60	60	N	O
)	)	)	)	)	N	O
41	CD	41	41	41	N	O
(	(	(	(	(	N	O
37	CD	37	37	37	N	O
)	)	)	)	)	N	O
55	CD	55	55	55	N	O
(	(	(	(	(	N	O
51	CD	51	51	51	N	O
)	)	)	)	)	N	O
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
27	CD	27	27	27	N	O
)	)	)	)	)	N	O

lymphocyte	NN	lymphocyte	lymphocyte	lymphocyt	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

lymphocyte	JJ	lymphocyte	lymphocyte	lymphocyt	N	B-AdverseReaction
count	NN	count	count	count	N	I-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Serum	NNP	serum	serum	serum	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
35	CD	35	35	35	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

GGT	NNP	ggt	ggt	ggt	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

triglycerides	NNS	triglycerides	triglyceride	triglycerid	Y	O
(	(	(	(	(	N	O
hypertriglyceridemia	NN	hypertriglyceridemia	hypertriglyceridemia	hypertriglyceridemia	Y	B-AdverseReaction
)	)	)	)	)	N	O
62	CD	62	62	62	N	O
(	(	(	(	(	N	O
56	CD	56	56	56	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

hyperglycemia	NN	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
54	CD	54	54	54	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
50	CD	50	50	50	N	O
(	(	(	(	(	N	O
46	CD	46	46	46	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Summary	NNP	summary	summary	summari	N	O
of	IN	of	of	of	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Trials	NNP	trials	trial	trial	N	O
in	IN	in	in	in	N	O
Indolent	NNP	indolent	indolent	indol	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O

The	DT	the	the	the	N	O

safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
in	IN	in	in	in	N	O
146	CD	146	146	146	N	O
adults	NNS	adults	adult	adult	N	O
with	IN	with	with	with	N	O
indolent	NN	indolent	indolent	indol	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	O
lymphoma	NN	lymphoma	lymphoma	lymphoma	Y	O
treated	VBD	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
was	VBD	was	wa	wa	N	O
6.1	CD	6.1	6.1	6.1	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
0.3	CD	0.3	0.3	0.3	N	O
to	TO	to	to	to	N	O
26.4	CD	26.4	26.4	26.4	N	O
months	NNS	months	month	month	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
73	CD	73	73	73	N	O
(	(	(	(	(	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
were	VBD	were	were	were	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
resulted	VBD	resulted	resulted	result	N	O
in	IN	in	in	in	N	O
interruption	NN	interruption	interruption	interrupt	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
for	IN	for	for	for	N	O
78	CD	78	78	78	N	O
(	(	(	(	(	N	O
53%	CD	53%	53%	53%	N	O
)	)	)	)	)	N	O
subjects	NNS	subjects	subject	subject	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
reasons	NNS	reasons	reason	reason	N	O
for	IN	for	for	for	N	O
interruption	NN	interruption	interruption	interrupt	N	O
or	CC	or	or	or	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
were	VBD	were	were	were	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
elevated	JJ	elevated	elevated	elev	N	B-AdverseReaction
transaminases	NNS	transaminases	transaminase	transaminas	Y	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
provides	VBZ	provides	provides	provid	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
subjects	NNS	subjects	subject	subject	N	O
receiving	VBG	receiving	receiving	receiv	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
provides	VBZ	provides	provides	provid	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	JJ	emergent	emergent	emerg	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Subjects	NNS	subjects	subject	subject	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Indolent	NNP	indolent	indolent	indol	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O
Treated	NNP	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
BID	NN	bid	bid	bid	N	O

Zydelig	NNP	zydelig	zydelig	zydelig	N	O
MonotherapyN	NNP	monotherapyn	monotherapyn	monotherapyn	N	O
146	CD	146	146	146	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O

disorders	NNS	disorders	disorder	disord	N	O

diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
68	CD	68	68	68	N	O
(	(	(	(	(	N	O
47	CD	47	47	47	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O

nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
42	CD	42	42	42	N	O
(	(	(	(	(	N	O
29	CD	29	29	29	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
44	CD	44	44	44	N	O
(	(	(	(	(	N	O
30	CD	30	30	30	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
41	CD	41	41	41	N	O
(	(	(	(	(	N	O
28	CD	28	28	28	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

asthenia	RB	asthenia	asthenia	asthenia	Y	B-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
25	CD	25	25	25	N	O
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O

cough	NN	cough	cough	cough	Y	B-AdverseReaction
42	CD	42	42	42	N	O
(	(	(	(	(	N	O
29	CD	29	29	29	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
disorders	NNS	disorders	disorder	disord	N	O

rash	NN	rash	rash	rash	Y	B-AdverseReaction
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

night	NN	night	night	night	N	B-AdverseReaction
sweats	NNS	sweats	sweat	sweat	N	I-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

headache	NN	headache	headache	headach	Y	B-AdverseReaction
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
12	CD	12	12	12	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Table	JJ	table	table	tabl	N	O
5	CD	5	5	5	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
Patients	NNP	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Indolent	NNP	indolent	indolent	indol	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
Hodgkin	NNP	hodgkin	hodgkin	hodgkin	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O
Treated	NNP	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
150	CD	150	150	150	N	O
mg	NN	mg	mg	mg	N	O
BID	NN	bid	bid	bid	N	O

Zydelig	NNP	zydelig	zydelig	zydelig	N	O
MonotherapyN	NNP	monotherapyn	monotherapyn	monotherapyn	N	O
146	CD	146	146	146	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
Any	NNP	any	any	ani	N	O
Grade	NNP	grade	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O

Grades	NNS	grades	grade	grade	N	O

were	VBD	were	were	were	N	O
obtained	VBN	obtained	obtained	obtain	N	O
per	IN	per	per	per	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
version	NN	version	version	version	N	O
4.03	CD	4.03	4.03	4.03	N	O
.	.	.	.	.	N	O

Serum	NN	serum	serum	serum	N	O

chemistry	NN	chemistry	chemistry	chemistri	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
73	CD	73	73	73	N	O
(	(	(	(	(	N	O
50	CD	50	50	50	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
60	CD	60	60	60	N	O
(	(	(	(	(	N	O
41	CD	41	41	41	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Hematology	NNP	hematology	hematology	hematolog	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O

neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
78	CD	78	78	78	N	O
(	(	(	(	(	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
41	CD	41	41	41	N	O
(	(	(	(	(	N	O
28	CD	28	28	28	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
\n\n	NN	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
FATAL	NNP	fatal	fatal	fatal	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
TOXICITIES	NNP	toxicities	toxicity	toxic	N	B-AdverseReaction
:	:	:	:	:	N	O
HEPATIC	NNP	hepatic	hepatic	hepat	N	I-AdverseReaction
,	,	,	,	,	N	O
SEVERE	NNP	severe	severe	sever	N	B-Severity
DIARRHEA	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
COLITIS	NNP	colitis	colitis	coliti	Y	B-AdverseReaction
,	,	,	,	,	N	O
PNEUMONITIS	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INTESTINAL	NNP	intestinal	intestinal	intestin	N	B-AdverseReaction
PERFORATION	NNP	perforation	perforation	perfor	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
FATAL	NNP	fatal	fatal	fatal	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
TOXICITIES	NNP	toxicities	toxicity	toxic	N	B-AdverseReaction
:	:	:	:	:	N	O
HEPATIC	NNP	hepatic	hepatic	hepat	N	I-AdverseReaction
,	,	,	,	,	N	O
SEVERE	NNP	severe	severe	sever	N	B-Severity
DIARRHEA	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
COLITIS	NNP	colitis	colitis	coliti	Y	B-AdverseReaction
,	,	,	,	,	N	O
PNEUMONITIS	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INTESTINAL	NNP	intestinal	intestinal	intestin	N	B-AdverseReaction
PERFORATION	NNP	perforation	perforation	perfor	Y	I-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
reduce	VB	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
as	IN	as	a	as	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
or	CC	or	or	or	N	O
colitis	NN	colitis	colitis	coliti	Y	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
reduce	VB	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
as	IN	as	a	as	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	O
infiltrates	NNS	infiltrates	infiltrates	infiltr	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
as	IN	as	a	as	N	O
recommended	JJ	recommended	recommended	recommend	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
for	IN	for	for	for	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	O
perforation	NN	perforation	perforation	perfor	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
FATAL	NNP	fatal	fatal	fatal	N	B-AdverseReaction
AND	NNP	and	and	and	N	O
SERIOUS	NNP	serious	serious	seriou	N	B-Severity
TOXICITIES	NNP	toxicities	toxicity	toxic	N	B-AdverseReaction
:	:	:	:	:	N	O
HEPATIC	NNP	hepatic	hepatic	hepat	N	I-AdverseReaction
,	,	,	,	,	N	O
SEVERE	NNP	severe	severe	sever	N	B-Severity
DIARRHEA	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
COLITIS	NNP	colitis	colitis	coliti	Y	B-AdverseReaction
,	,	,	,	,	N	O
PNEUMONITIS	NNP	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INTESTINAL	NNP	intestinal	intestinal	intestin	N	B-AdverseReaction
PERFORATION	NNP	perforation	perforation	perfor	Y	I-AdverseReaction
\n	NNP	\n	\n	\n	N	O
\n\n	NNP	\n\n	\n\n	\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
and	CC	and	and	and	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
reduce	VB	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
or	CC	or	or	or	N	O
colitis	NN	colitis	colitis	coliti	Y	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
and	CC	and	and	and	N	O
then	RB	then	then	then	N	O
reduce	VB	reduce	reduce	reduc	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
and	CC	and	and	and	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	O
infiltrates	NNS	infiltrates	infiltrates	infiltr	N	O
.	.	.	.	.	N	O

Interrupt	NNP	interrupt	interrupt	interrupt	N	O
or	CC	or	or	or	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
can	MD	can	can	can	N	O
occur	VB	occur	occur	occur	N	O
in	IN	in	in	in	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
if	IN	if	if	if	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	O
perforation	NN	perforation	perforation	perfor	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
\n	VBD	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
:	:	:	:	:	N	O
monitor	NN	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
may	MD	may	may	may	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
potential	JJ	potential	potential	potenti	N	O
risk	NN	risk	risk	risk	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O

Fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction

and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

Elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	B-Severity
times	NNS	times	time	time	N	I-Severity
the	DT	the	the	the	N	I-Severity
upper	JJ	upper	upper	upper	N	I-Severity
limit	NN	limit	limit	limit	N	I-Severity
of	IN	of	of	of	N	I-Severity
normal	JJ	normal	normal	normal	N	I-Severity
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
observed	VBN	observed	observed	observ	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
reversible	JJ	reversible	reversible	revers	N	O
with	IN	with	with	with	N	O
dose	JJ	dose	dose	dose	N	O
interruption	NN	interruption	interruption	interrupt	N	O
.	.	.	.	.	N	O

After	IN	after	after	after	N	O
resumption	NN	resumption	resumption	resumpt	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
,	,	,	,	,	N	O
26%	CD	26%	26%	26%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
recurrence	NN	recurrence	recurrence	recurr	N	B-AdverseReaction
of	IN	of	of	of	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	I-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
for	IN	for	for	for	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
liver	NN	liver	liver	liver	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
ALT	NNP	alt	alt	alt	N	O
and	CC	and	and	and	N	O
AST	NNP	ast	ast	ast	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
every	DT	every	every	everi	N	O
2	CD	2	2	2	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
every	DT	every	every	everi	N	O
4	CD	4	4	4	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
then	RB	then	then	then	N	O
every	DT	every	every	everi	N	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
weekly	JJ	weekly	weekly	weekli	N	O
for	IN	for	for	for	N	O
liver	JJ	liver	liver	liver	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
ALT	NNP	alt	alt	alt	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
rises	NNS	rises	rise	rise	N	O
above	IN	above	above	abov	N	O
3	CD	3	3	3	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
until	IN	until	until	until	N	O
resolved	VBN	resolved	resolved	resolv	N	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
ALT	NNP	alt	alt	alt	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
is	VBZ	is	is	is	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5	CD	5	5	5	N	O
times	NNS	times	time	time	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
continue	VB	continue	continue	continu	N	O
to	TO	to	to	to	N	O
monitor	VB	monitor	monitor	monitor	N	O
AST	NNP	ast	ast	ast	N	O
,	,	,	,	,	N	O
ALT	NNP	alt	alt	alt	N	O
and	CC	and	and	and	N	O
total	JJ	total	total	total	N	O
bilirubin	JJ	bilirubin	bilirubin	bilirubin	Y	O
weekly	JJ	weekly	weekly	weekli	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
abnormality	NN	abnormality	abnormality	abnorm	N	O
is	VBZ	is	is	is	N	O
resolved	VBN	resolved	resolved	resolv	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Severe	NNP	severe	severe	sever	N	O
Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	O
or	CC	or	or	or	N	O
Colitis	NNP	colitis	colitis	coliti	Y	O

Severe	JJ	severe	severe	sever	N	B-Severity
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
or	CC	or	or	or	N	O
colitis	NN	colitis	colitis	coliti	Y	B-AdverseReaction
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
higher	JJR	higher	higher	higher	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
14%	CD	14%	14%	14%	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
at	IN	at	at	at	N	O
any	DT	any	any	ani	N	O
time	NN	time	time	time	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
concurrent	NN	concurrent	concurrent	concurr	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
that	WDT	that	that	that	N	O
cause	VBP	cause	cause	caus	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
.	.	.	.	.	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
responds	VBZ	responds	responds	respond	N	O
poorly	RB	poorly	poorly	poorli	N	O
to	TO	to	to	to	N	O
antimotility	NN	antimotility	antimotility	antimotil	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

Median	JJ	median	median	median	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
resolution	VB	resolution	resolution	resolut	N	O
ranged	VBN	ranged	ranged	rang	N	O
between	IN	between	between	between	N	O
1	CD	1	1	1	N	O
week	NN	week	week	week	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
across	IN	across	across	across	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
following	VBG	following	following	follow	N	O
interruption	NN	interruption	interruption	interrupt	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
some	DT	some	some	some	N	O
instances	NNS	instances	instance	instanc	N	O
,	,	,	,	,	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
who	WP	who	who	who	N	O
present	VBP	present	present	present	N	O
with	IN	with	with	with	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
cough	NN	cough	cough	cough	Y	O
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	O
,	,	,	,	,	N	O
hypoxia	NN	hypoxia	hypoxia	hypoxia	Y	O
,	,	,	,	,	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	O
infiltrates	NNS	infiltrates	infiltrates	infiltr	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
radiologic	JJ	radiologic	radiologic	radiolog	N	O
exam	NN	exam	exam	exam	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
a	DT	a	a	a	N	O
decline	NN	decline	decline	declin	N	O
by	IN	by	by	by	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
5%	CD	5%	5%	5%	N	O
in	IN	in	in	in	N	O
oxygen	NN	oxygen	oxygen	oxygen	N	O
saturation	NN	saturation	saturation	satur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
for	IN	for	for	for	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
is	VBZ	is	is	is	N	O
suspected	VBN	suspected	suspected	suspect	N	O
,	,	,	,	,	N	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
until	IN	until	until	until	N	O
the	DT	the	the	the	N	O
etiology	NN	etiology	etiology	etiolog	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
pulmonary	NN	pulmonary	pulmonary	pulmonari	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	O
thought	VBN	thought	thought	thought	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
caused	VBN	caused	caused	caus	N	O
by	IN	by	by	by	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Intestinal	JJ	intestinal	intestinal	intestin	N	O
Perforation	NN	perforation	perforation	perfor	Y	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
and	CC	and	and	and	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
the	DT	the	the	the	N	O
time	NN	time	time	time	N	O
of	IN	of	of	of	N	O
perforation	NN	perforation	perforation	perfor	Y	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
moderate	JJ	moderate	moderate	moder	N	B-Severity
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	B-Severity
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
promptly	VB	promptly	promptly	promptli	N	O
report	VB	report	report	report	N	O
any	DT	any	any	ani	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	JJ	worsening	worsening	worsen	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	O
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
permanently	RB	permanently	permanently	perman	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	O
perforation	NN	perforation	perforation	perfor	Y	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Severe	NNP	severe	severe	sever	N	O
Cutaneous	NNP	cutaneous	cutaneous	cutan	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

One	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
toxic	NN	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
(	(	(	(	(	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
and	CC	and	and	and	N	O
bendamustine	NN	bendamustine	bendamustine	bendamustin	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
severe	JJ	severe	severe	sever	N	B-Severity
or	CC	or	or	or	N	O
life	NN	life	life	life	N	B-Severity
-	:	-	-	-	N	I-Severity
threatening	NN	threatening	threatening	threaten	N	I-Severity
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
)	)	)	)	)	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
exfoliative	NN	exfoliative	exfoliative	exfoli	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	VBP	rash	rash	rash	Y	B-AdverseReaction
erythematous	JJ	erythematous	erythematous	erythemat	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	JJ	rash	rash	rash	Y	B-AdverseReaction
generalized	VBN	generalized	generalized	gener	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	VB	rash	rash	rash	Y	B-AdverseReaction
macular	NN	macular	macular	macular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
maculo	SYM	maculo	maculo	maculo	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
papular	NN	papular	papular	papular	N	I-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
pruritic	NN	pruritic	pruritic	prurit	N	I-AdverseReaction
,	,	,	,	,	N	O
exfoliative	JJ	exfoliative	exfoliative	exfoli	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
development	NN	development	development	develop	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
cutaneous	JJ	cutaneous	cutaneous	cutan	N	O
reactions	NNS	reactions	reaction	reaction	N	O
and	CC	and	and	and	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O

Serious	JJ	serious	serious	seriou	N	B-Severity
allergic	JJ	allergic	allergic	allerg	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
serious	JJ	serious	serious	seriou	N	O
allergic	JJ	allergic	allergic	allerg	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
permanently	RB	permanently	permanently	perman	N	O
and	CC	and	and	and	N	O
institute	VB	institute	institute	institut	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
supportive	JJ	supportive	supportive	support	N	O
measures	NNS	measures	measure	measur	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O

Treatment	NNP	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
emergent	NN	emergent	emergent	emerg	N	O
Grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
neutropenia	NNS	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
31%	CD	31%	31%	31%	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
across	IN	across	across	across	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
every	DT	every	every	everi	N	O
two	CD	two	two	two	N	O
weeks	NNS	weeks	week	week	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
3	CD	3	3	3	N	O
months	NNS	months	month	month	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
weekly	JJ	weekly	weekly	weekli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
while	IN	while	while	while	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	O
counts	NNS	counts	count	count	N	O
are	VBP	are	are	are	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
1.0	CD	1.0	1.0	1.0	N	O
Gi	NNP	gi	gi	gi	N	O
L	NNP	l	l	l	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

Based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
findings	NNS	findings	finding	find	N	O
in	IN	in	in	in	N	O
animals	NNS	animals	animal	anim	N	B-Animal
,	,	,	,	,	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
may	MD	may	may	may	N	O
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Idelalisib	NNP	idelalisib	idelalisib	idelalisib	N	O
is	VBZ	is	is	is	N	O
teratogenic	JJ	teratogenic	teratogenic	teratogen	N	B-AdverseReaction
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
systemic	JJ	systemic	systemic	system	N	O
exposures	NNS	exposures	exposure	exposur	N	O
12	CD	12	12	12	N	O
times	NNS	times	time	time	N	O
those	DT	those	those	those	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
150	CD	150	150	150	N	O
mg	JJ	mg	mg	mg	N	O
twice	RB	twice	twice	twice	N	O
daily	RB	daily	daily	daili	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Advise	NNP	advise	advise	advis	N	O
females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
reproductive	JJ	reproductive	reproductive	reproduct	N	O
potential	NN	potential	potential	potenti	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
contraceptive	JJ	contraceptive	contraceptive	contracept	N	O
methods	NNS	methods	method	method	N	O
are	VBP	are	are	are	N	O
being	VBG	being	being	be	N	O
considered	VBN	considered	considered	consid	N	O
,	,	,	,	,	N	O
use	VBP	use	use	use	N	O
effective	JJ	effective	effective	effect	N	O
contraception	NN	contraception	contraception	contracept	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
for	IN	for	for	for	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
month	NN	month	month	month	N	O
after	IN	after	after	after	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
Zydelig	NNP	zydelig	zydelig	zydelig	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

